Stock Analiz

Aquestive Therapeutics, Inc. AQST

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$3.91Market cap $491M
Open the interactive analysis →

Aquestive Therapeutics, Inc. (AQST) is a healthcare company listed in the US with a market value of about $491M. In the twelve months to September 30, 2026 it had revenue of $49M and net income of -$79M, a net margin of -162.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -1% a year, a 5-year average ROIC of -436%.

About Aquestive Therapeutics

Aquestive Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $67M in 2017 to $45M in 2025, a decline of about 5.0% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 119% over three years (dilution for shareholders). It spends 39% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S10.1
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-8.3%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-22.6%
Revenue growth (5 yrs, per year)-0.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-106.6%
ROIC (5-yr avg.)-435.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$49M$45M$58M$51M$48M$51M$46M$53M$67M$67M
Net income-$79M-$84M-$44M-$8M-$54M-$71M-$56M-$66M-$61M-$9M
Free cash flow-$41M-$53M-$36M-$7M-$11M-$34M-$46M-$61M-$15M$4M
EPS (diluted)$-0.65$-0.78$-0.51$-0.13$-1.12$-1.85$-1.66$-2.61$-2.96—
Net margin-162.3%-188.1%-76.7%-15.6%-114.1%-138.8%-121.7%-125.9%-91.0%-13.4%
ROIC—-435.7%————-652.2%-82.5%-333.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $9.33, 139% above the current price; targets range from $6.00 to $11.00; the consensus rating is “Strong buy”; expected EPS is $-0.40 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Aquestive Therapeutics pay a dividend?

Not currently.

Is Aquestive Therapeutics a good stock to buy?

We do not give buy or sell advice. Aquestive Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.